Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TScan Therapeutics Inc TCRX

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual... see more

Recent & Breaking News (NDAQ:TCRX)

TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

GlobeNewswire September 9, 2021

TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

GlobeNewswire September 2, 2021

TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

GlobeNewswire August 19, 2021

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

GlobeNewswire July 21, 2021

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

GlobeNewswire July 15, 2021